We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) closed at $2.06 in the latest trading session, marking a -3.74% move from the prior day. This change lagged the S&P 500's daily loss of 1.21%. On the other hand, the Dow registered a gain of 0.02%, and the technology-centric Nasdaq decreased by 2.6%.
The maker of genetic analysis technology's stock has climbed by 51.77% in the past month, exceeding the Medical sector's gain of 2.71% and the S&P 500's loss of 0.03%.
Market participants will be closely following the financial results of Pacific Biosciences of California in its upcoming release. The company plans to announce its earnings on November 4, 2026. The company's earnings per share (EPS) are projected to be -$0.13, reflecting a 8.33% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $37.86 million, reflecting a 1.52% fall from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.43 per share and revenue of $156.1 million, which would represent changes of +18.87% and -2.44%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Pacific Biosciences of California. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Pacific Biosciences of California presently features a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 102, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Pacific Biosciences of California (PACB - Free Report) closed at $2.06 in the latest trading session, marking a -3.74% move from the prior day. This change lagged the S&P 500's daily loss of 1.21%. On the other hand, the Dow registered a gain of 0.02%, and the technology-centric Nasdaq decreased by 2.6%.
The maker of genetic analysis technology's stock has climbed by 51.77% in the past month, exceeding the Medical sector's gain of 2.71% and the S&P 500's loss of 0.03%.
Market participants will be closely following the financial results of Pacific Biosciences of California in its upcoming release. The company plans to announce its earnings on November 4, 2026. The company's earnings per share (EPS) are projected to be -$0.13, reflecting a 8.33% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $37.86 million, reflecting a 1.52% fall from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.43 per share and revenue of $156.1 million, which would represent changes of +18.87% and -2.44%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Pacific Biosciences of California. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Pacific Biosciences of California presently features a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 102, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.